AUTHOR QUERY FORM

ELSEVIER

Journal: CAR

Article Number: 6420

Please e-mail or fax your responses and any corrections to:

E-mail: corrections.essd@elsevier.sps.co.in

Fax: +31 2048 52799

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

Location in article	Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof
Q1	The article title has been modified. Please check, and correct if necessary.
Q2	Please confirm that given names and surnames have been identified correctly.

Please check this box if you have no corrections to make to the PDF file ☐

Thank you for your assistance.

Graphical abstract

Synthesis of 2-(β-D-glucopyranosyl)-5-(substituted-amino)-1,3,4-oxa- and -thiadiazoles for the inhibition of glycogen phosphorylase pp xxx–xxx

Béla Szőcs, Marietta Tóth *, Tibor Docsa, Pál Gergely, László Somsák *



Highlights

• Preparation of new anhydro-aldose semicarbazones and thiosemicarbazones. • Synthesis of 2-acylamino- or 2-arylamino-5-(β-D-glucopyranosyl)-1,3,4-oxa- and -thiadiazoles. • Low micromolar inhibitor of glycogen phosphorylase.

Carbohydrate Research xxx (2013) xxx–xxx

Contents lists available at SciVerse ScienceDirect

Carbohydrate Research

journal homepage: www.elsevier.com/locate/carres

Synthesis of 2-(β-D-glucopyranosyl)-5-(substituted-amino)-1,3,4-oxa- and -thiadiazoles for the inhibition of glycogen phosphorylase

Béla Szőcs[a], Marietta Tóth[a,*], Tibor Docsa[b], Pál Gergely[b], László Somsák[a,*]

[a] Department of Organic Chemistry, University of Debrecen, POB 20, H-4010 Debrecen, Hungary
[b] Department of Medical Chemistry, Medical and Health Science Centre, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary

ARTICLE INFO

Article history:
Received 19 January 2013
Received in revised form 8 March 2013
Accepted 12 March 2013
Available online xxxx

Keywords:
C-Glycosyl-formaldehyde
(thio)semicarbazone
C-Glycosyl-1,3,4-oxadiazole
C-Glycosyl-1,3,4-thiadiazole
Glycogen phosphorylase
Inhibitor

ABSTRACT

O-Perbenzoylated 4-phenyl-[*C*-(β-D-glucopyranosyl)formaldehyde]semicarbazone was prepared in the reaction of *O*-perbenzoylated β-D-glucopyranosyl cyanide and 4-phenylsemicarbazide in the presence of Raney-Ni. Acylation of *O*-perbenzoylated *C*-(β-D-glucopyranosyl)formaldehyde semicarbazone furnished the corresponding 4-acyl-[*C*-(β-D-glucopyranosyl)formaldehyde]semicarbazones. The reaction of *O*-perbenzoylated *C*-(β-D-glucopyranosyl)formaldehyde semicarbazone with the corresponding thiosemicarbazide resulted in *O*-perbenzoylated *C*-(β-D-glucopyranosyl)formaldehyde thiosemicarbazone and its 4-phenyl derivative. Acylation of *O*-perbenzoylated *C*-(β-D-glucopyranosyl)formaldehyde thiosemicarbazone provided the corresponding 4-acyl-2-acylamino-5-(β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazolidines. Oxidative transformations of these precursors gave *O*-protected 2-(β-D-glucopyranosyl)-5-substituted-amino-1,3,4-oxa- and -thiadiazoles. The *O*-benzoyl protecting groups were removed under base-catalysed transesterification conditions. The *C*-glucopyranosyl heterocyclic compounds proved inactive against rabbit muscle glycogen phosphorylase *b*, however, the semicarbazones showed moderate inhibition (best inhibitor was 4-phenyl-[*C*-(β-D-glucopyranosyl)formaldehyde]semicarbazone (K_i = 29 μM).

1. Introduction

Glycogen phosphorylase (EC 2.4.1.1) inhibitors (GPIs) have been considered as possible means for therapeutic intervention in type 2 diabetes and some other diseased states (e.g., early cardiac and cardiovascular disease in non-diabetics, cardiac arrhythmias, ischaemic injuries, and tumour growth) as rationalized in the recent review literature.[1–5] Among several compound classes[4,6] glucose derivatives are one of the most intensively investigated inhibitors.[5,7] The quoted review articles[5,7] provide the reader with a detailed description of the structure–activity relationships (SAR) of glucose analogue GPIs, therefore, only those features are summarized hereinafter which form the direct basis of our compound design. *N*-Acyl-β-D-glucopyranosylamines[8] (Chart 1, **I**: e.g. for R = 2-naphthyl K_i measured against rabbit muscle GP*b* (RMGP*b*)[9] was 10–13 μM,[8,10]) *N*-aryl-*N*′-β-D-glucopyranosyl ureas[4,11] **II** (R = 2-naphthyl: K_i (RMGP*b*) 5.2 μM), as well as *N*-acyl-*N*′-β-D-glucopyranosyl urea derivatives[4,12] **III** (R = 2-naphthyl: K_i (RMGP*b*) 0.35 μM) have been shown to inhibit the enzyme in the low micromolar range. As a part of a programme to replace the NHCO moiety of the above compounds by non-classical bioisosteric heterocyclic linkers, among others we have carried out the synthesis of compounds **IA**.[13] Enzymatic tests as well as crystallographic studies revealed high similarity of the amide (see K_i of **I** above) and the 1,2,3-triazole type (for **IA** R = 2-naphthyl: K_i (RMGPb) 16 μM) inhibitors both in binding strength and structural features of the enzyme–inhibitor complexes.[10] Applying the isomeric oxadiazoles **B**, **D**, and **E** as linkers resulted in inhibitors of varying efficiency, whereby the 3-aryl-5-β-D-glucopyranosyl-1,2,4-oxadiazole (**IE** type) derivatives proved to be the most potent compounds (for the best inhibitor where R = 2-naphthyl the K_i (RMGPb) was 2.4 μM).[14,15]

Herein we report on the synthesis and enzymatic test of compounds of type **II** and **III** with 1,3,4-oxadiazole **B** and 1,3,4-thiadiazole **C** as linkers representing bioisosteric replacements of NHCO moieties of *N*-substituted-*N*′-β-D-glucopyranosyl ureas. These studies contribute to an extension of SAR related to interactions of inhibitors in the β-channel of the enzyme which can accommodate aglycons of the glucose analogue compounds and is lined with amino acid side chains of mixed character.[16]

2. Results and discussion

For the formation of the heterocyclic parts of the target compounds oxidative ring closure of (thio)semicarbazones (similar to

* Corresponding authors. Tel.: +36 52512900x22474; fax: +36 52512744 (M.T.); tel.: +36 52512900x22348; fax: +36 52512744 (L.S.).
E-mail addresses: toth.marietta@science.unideb.hu (M. Tóth), somsak.laszlo@science.unideb.hu (L. Somsák).

0008-6215/$ - see front matter © 2013 Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.carres.2013.03.009



Chart 1.

that applied for the syntheses of **IB**[15]) was envisaged as the key step. To this end, the protected *C*-(β-D-glucopyranosyl)formaldehyde semicarbazone **2** was prepared by a reaction of $NH_2C(=O)NHNH_2$ with O-perbenzoylated β-D-glucopyranosyl cyanide[17] **1** in the presence of Raney Ni and NaH_2PO_2 at 40 °C (Scheme 1) as described earlier.[18] O-Perbenzoylated 4-phenyl-[*C*-(β-D-glucopyranosyl)formaldehyde]semicarbazone **3** was obtained in a similar way using $PhNHC(=O)NHNH_2$ as the trapping agent. Debenzoylation was performed by the Zemplén protocol to result in moderate yields of semicarbazones **6** and **7**.

In order to get thiosemicarbazones **4** and **5**, acid catalysed transimination of **2** was carried out because the direct transformation of β-D-glucopyranosyl cyanide **1** into thiosemicarbazones failed. Thus, semicarbazone **2** was reacted with $NH_2C(=S)NHNH_2$ or $PhNHC(=S)NHNH_2$ in glacial AcOH at 70 °C to give the corresponding thiosemicarbazones **4** and **5**, respectively. Removal of the benzoyl protecting groups in **4** and **5** was carried out by LiOH in MeOH to give compounds **8** and **9**, respectively, in satisfactory yields.

To obtain precursors for compounds **IIIB** semicarbazone **2** was treated by acid chlorides in CH_2Cl_2 in the presence of Et_3N to give O-perbenzoylated 4-acyl-[*C*-(β-D-glucopyranosyl)formaldehyde] semicarbazones **12–15** in satisfactory yields (Scheme 2). Under these conditions no reaction took place with thiosemicarbazone **3**. Acylation of **3** in dry pyridine at 80 °C resulted in the formation of 4-acyl-2-acylamino-5-(β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazolines **16–19** as inseparable mixtures of two diastereoisomers in good yields. This observation is in accord with the literature experiences.[19]

Ring closing reactions of the precursors under oxidative conditions were studied next. Semicarbazone **3** was reacted with Pb $(OAc)_4$ in glacial AcOH at 70 °C to furnish O-perbenzoylated 2-phenylamino-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,



Scheme 1. Reagents and conditions: (a) $RNHC(=O)NHNH_2$, Raney Ni, NaH_2PO_2, H_2O, AcOH, pyridine, 40 °C; (b) $RNHC(=S)NHNH_2$, AcOH, 70 °C; (c) NaOMe, dry MeOH, 25 °C; (d) LiOH, dry MeOH, 0 °C.



		X = O	X = S	X = O	X = S
R = CH_3	**12** (47 %)	**20** (50 %)	**24** (67 %)	**28** (41 %)	**32** (92 %)
R = Ph	**13** (70 %)	**21** (57 %)	**25** (68 %)	**29** (87 %)	**33** (68 %)
R = 2-Naphthyl	**14** (50 %)	**22** (69 %)	**26** (59 %)	**30** (93 %)	**34** (57 %)
R = 4-*t*Bu-C_6H_4	**15** (55 %)	**23** (60 %)	**27** (84 %)	**31** (76 %)	**35** (72 %)

Scheme 2. Reagents and conditions: (a) $Pb(OAc)_4$, AcOH, 70 °C; (b) NaOMe, dry MeOH, 25 °C; (c) RCOCl, Et_3N, dry CH_2Cl_2; (d) RCOCl, dry pyridine, 80 °C; (e) PIDA, CH_2Cl_2, 25 °C.

Please cite this article in press as: Szőcs, B.; et al. *Carbohydr. Res.* (2013), http://dx.doi.org/10.1016/j.carres.2013.03.009

Table 1
Inhibition of rabbit muscle glycogen phosphorylase b (RMGPb) by selected glucose derivatives and the new compounds (K_i [μM])



II

Entry	Linker	R		R	
1	NHCO				
		18[4]		**11** No inh.[a]	



III

Entry	Linker	R: CH_3	R: 	R: 	R: 
2	NHCO	305[21]	4.6[21]	0.35[4]	0.7[4]
3		**28** No inh.[a]	**29** No inh.[a]	**30** No inh.[a]	**31** No inh.[a]
4		**32** No inh.[a]	**33** No inh.[a]	**34** No inh.[a]	**35** No inh.[a]



IV

Entry	Linker	X	R: H	R: 
5	NHCO	O	–	21[4]
6	CH=N	O	**6** 332[b]	**7** 29
7	CH=N	S	**8** No inh.	**9** 300[b]

[a] No inhibition at a tested concentration of 625 μM.
[b] Calculated from the IC_{50} value by using a web-based tool.[22]

3,4-ox adiazole **10** (Scheme 2). Trials to use other oxidizing agents such as $FeCl_3$ or PIDA failed, **3** was recovered in these reactions. Deprotection of **10** was achieved by the Zemplén method to give **11** in an excellent yield. Thiosemicarbazone **4** resisted several oxidation reagents (PIDA, $Pb(OAc)_4$, $FeCl_3$, Br_2, and $K_3Fe(CN)_6$). Semicarbazones **12–15** were reacted with PIDA in CH_2Cl_2 at rt to get O-perbenzoylated 2-acylamino-5-(β-D-glucopyranosyl)-1,3,4-oxadiazoles **20–23** in good yields (Scheme 2). Thiadiazolines **16–19** were oxidized in a similar way to result in 1,3,4-thiadiazoles **24–27**. Debenzoylations were performed by the Zemplén protocol to give good and excellent yields of 1,3,4-oxadiazoles **28–31** and 1,3,4-thiadiazoles **32–35**.

The deprotected compounds were tested for their inhibition potency against rabbit muscle glycogen phosphorylase *b* (RMGP*b*) according to the protocol described earlier.[20] The results are summarized in Table 1 also showing the inhibitory efficiency of some relevant reference compounds.

Replacement of the NHCO moiety in compound type **II** (entry 1) by a 1,3,4-oxadiazole ring (**11**) resulted in a loss of inhibition. A similar observation was made with compounds type **III** whereby on changing the NHCO group of the acylurea derivatives (entry 2) to either 1,3,4-oxadiazole (entry 3, **28–31**) or 1,3,4-thiadiazole (entry 4, **32–35**) the efficiency was lost. These findings resemble those obtained with compounds type **IB** in Chart 1 where 1,3,4-oxadiazole replacements in *N*-acyl-glucopyranosylamines resulted in practically inactive compounds.[15] It follows from these results that the 1,3,4-oxadiazole and 1,3,4-thiadiazole moieties cannot contribute to favourable interactions in the β-channel of RMGP*b*.

Interestingly, semicarbazones **6** and **7** (entry 6) and thiosemicarbazones **8** and **9** (entry 7), the 'open chain' precursors of the target compounds of this work, showed week to moderate inhibition. Semicarbazones **6** and **7** are better inhibitors than the thiosemicarbazone counterparts **8** and **9**. Phenyl derivatives **7** and **9** are more efficient than the unsubstituted compounds **6** and **8**, respectively, and this is in agreement with the general trend to show stronger inhibition by those compounds which have a large(r) aromatic part in the aglycon.[4] A comparison of **7** (actually the best inhibitor in this study) to the biuret type inhibitor (entry 5) indicates no significant difference in the inhibition constants. This may reveal that interactions of the whole NHCO linker moiety or its carbonyl group has probably less significance in binding to the enzyme than those of the 'second' NHCO unit.

3. Conclusion

The reductive transformation of D-glycopyranosyl cyanides in the presence of acylhydrazines was extended to the preparation of new anhydro-aldose semicarbazone and thiosemicarbazone derivatives. Acylation of semicarbazones yielded the expected 4-acyl semicarbazones, while under similar conditions thiosemicarbazones gave O-peracylated 4-acyl-2-acylamino-5-(β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazolines. Oxidation of the aforementioned precursors resulted in protected 2-(β-D-glucopyranosyl)-5-(substituted-amino)-1,3,4-oxa- and thiadiazoles, respectively. After O-deprotection enzyme kinetic measurements showed the 1,3,4-oxa- and -thiadiazoles to be inactive against rabbit muscle

glycogen phosphorylase *b*. However, the precursor 'open chain' 4-phenyl semicarbazone proved to be a low micromolar GPI, equipotent with a biuret derivative of similar chain length between the sugar and the aromatic part of the molecule. Replacement of the oxygen by a sulfur atom caused the loss of activity. This latter finding may indicate a difference in contribution to the binding of the two NHCO unites of *N*-acyl-*N*′-glucopyranosyl urea type inhibitors of glycogen phosphorylase.

4. Experimental

4.1. General methods

Melting points were measured in open capillary tubes or on a Kofler hot-stage and are uncorrected. Optical rotations were determined with a Perkin–Elmer 241 polarimeter at room temperature. NMR spectra were recorded with Bruker 360 (360/90 MHz for $^1H/^{13}C$) or Bruker 400 (400/100 MHz for $^1H/^{13}C$) spectrometers. Chemical shifts are referenced to TMS as the internal reference (^1H), or to the residual solvent signals (^{13}C). Microanalyses were performed on an Elementar vario Micro cube. ESI-MS were recorded with a Thermo Scientific LTQ XL instrument. TLC was performed on DC-Alurolle Kieselgel 60 F_{254} (Merck). TLC plates were visualized under UV light, and by gentle heating with a commercially available heat gun without any charring reagent. For column chromatography Kieselgel 60 (Merck, particle size (0.063–0.200 mm) was applied. Organic solutions were dried over anhydrous $MgSO_4$, and concentrated under diminished pressure at 40–50 °C (water bath).

4.2. 4-Phenyl-[*C*-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl) formaldehyde]semicarbazone (3)

Raney Ni (3.53 g, from an aqueous suspension, Merck) was added at rt to a vigorously stirred solution of pyridine (14 mL), H_2O (9 mL), and AcOH (9 mL). Then, NaH_2PO_2 (1.76 g, 20.0 mmol), (2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl) cyanide[17] (**1**, 1.50 g, 2.48 mmol), and PhNHC(=O)NHNH$_2$ (0.75 g, 4.96 mmol) were added to the mixture. The reaction mixture was stirred and heated at 40 °C. When the reaction was complete (TLC, 1:2 EtOAc/hexane) the insoluble materials were filtered off with suction, and washed with EtOAc (3 × 15 mL). The organic layer of the filtrate was separated, washed with 10% HCl (2 × 15 mL), saturated $NaHCO_3$ solution (3 × 20 mL), H_2O (2 × 15 mL), dried, and concentrated under reduced pressure. Traces of pyridine were removed by repeated co-evaporations with toluene. The crude product was purified by column chromatography (2:3 EtOAc/hexane) to yield 1.17 g (64%) of **3** as a white amorphous product. $[\alpha]_D$ = +33 (*c* 0.52, $CHCl_3$); R_f: 0.44 (1:1 EtOAc/hexane); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 10.36 (1H, s, N*H*), 8.20 (1H, s, NH), 8.05–7.02 (26H, m, Ar, CH=N), 6.08, 6.03, 5.77 (3H, 3 pt, J = 9.2, 9.5 Hz in each, H-2, H-3, H-4), 4.67 (1H, dd, $J_{6a,6b}$ = 12.7 Hz, H-6a), 4.53 (1H, dd, $J_{1,CH=N}$ = 4.1 Hz, $J_{1,2}$ = 9.1 Hz, H-1), 4.40 (1H, dd, H-6b), 4.25 (1H, ddd, $J_{5,6a}$ = 3.0 Hz, $J_{5,6b}$ = 4.5 Hz, $J_{4,5}$ = 9.9 Hz, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.0, 165.8, 165.0 (CO), 153.7 (NHCONH), 138.0 (CH=N), 136.5–119.4 (Ar), 76.3, 76.2, 74.3, 69.3 (C-1 to C-5), 63.0 (C-6). Anal. Calcd for $C_{42}H_{35}N_3O_{10}$ (741.74): C, 68.01, H, 4.76; N, 5.67. Found: C, 69.00; H, 4.83; N, 5.62.

4.3. *C*-(2,3,4,6-Tetra-*O*-benzoyl-β-D-glucopyranosyl) formaldehyde thiosemicarbazone (4)

C-(2,3,4,6-Tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde semicarbazone[18] (**2**, 1.50 g, 2.25 mmol) was dissolved in glacial AcOH (65 mL) and then $NH_2C(=S)NHNH_2$ (0.83 g, 9.05 mmol) was added. The mixture was stirred and heated at 70 °C. The reaction was monitored by TLC (1:1 EtOAc/hexane). When the reaction was complete, the reaction mixture was diluted with H_2O (200 mL), and extracted with EtOAc (4 × 20 mL), and washed with $NaHCO_3$ (3 × 25 mL), and H_2O (1 × 20 mL). The organic phase was dried ($MgSO_4$), and evaporated under reduced pressure. The crude product was purified by column chromatography (1:1 EtOAc/hexane) to give 1.30 g (85%) of **4** as a yellow amorphous product **4**. $[\alpha]_D$ = +11 (*c* 0.35, $CHCl_3$); R_f: 0.33 (1:2 EtOAc/hexane); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 9.94 (1H, s, NH), 8.07–7.10 (21H, m, Ar, CH=N), 6.34 (1H, s, J = 2.4 Hz, N*H*), 5.98, 5.87, 5.71 (3H, 3 pt, J = 9.5, 9.8 Hz in each, H-2, H-3, H-4), 4.66 (1H, dd, $J_{6a,6b}$ = 12.5 Hz, H-6a), 4.49–4.43 (2H, m, H-1, H-6b), 4.22 (1H, ddd, $J_{5,6a}$ = 2.9 Hz, $J_{5,6b}$ = 5.0 Hz, $J_{4,5}$ = 9.9 Hz, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 179.2 (CS), 166.1, 165.9, 165.8, 165.1 (CO), 139.2 (CH=N), 133.7–128.3 (Ar), 76.9, 76.4, 73.9, 69.6, 69.1 (C-1 to C-5), 62.9 (C-6). Anal. Calcd for $C_{36}H_{31}N_3O_9S$ (681.71): C, 63.43, H, 4.58; N, 6.16; S, 4.70. Found: C, 63.54; H, 4.67; N, 6.09; S, 4.78.

4.4. 4-Phenyl-[C-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde]thiosemicarbazone (5)

C-(2,3,4,6-Tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde semicarbazone[18] (**2**, 1.00 g, 1.50 mmol) was dissolved in glacial AcOH (43 mL) and then PhNHC(=S)NHNH$_2$ (0.83 g, 9.05 mmol) was added. The mixture was stirred and heated at 70 °C. The reaction was monitored by TLC (1:1 EtOAc/hexane). When the reaction was complete, the reaction mixture was diluted with H_2O (150 mL), and extracted with EtOAc (4 × 15 mL), and washed with $NaHCO_3$ (3 × 20 mL), and H_2O (1 × 15 mL). The organic phase was dried ($MgSO_4$), and evaporated under reduced pressure. The crude product was purified by column chromatography (1:1.5 EtOAc/hexane) to yield 1.00 g (87%) of **5** as a yellow amorphous product. $[\alpha]_D$ = +7 (*c* 0.33, $CHCl_3$); R_f: 0.55 (1:1 EtOAc/hexane); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 10.74 (1H, s, NH), 9.19 (1H, s, NH), 8.04–7.18 (26H, m, Ar, CH=N), 6.09–5.99 (2H, m, H-2 and/or H-3 and/or H-4), 5.76 (1H, 1 pt, J = 9.3 Hz, H-2 or H-3 or H-4), 4.66 (1H, dd, $J_{5,6a}$ = 2.4 Hz, $J_{6a,6b}$ = 12.2 Hz, H-6a), 4.54 (1H, dd, $J_{1,CH=N}$ = 4.0 Hz, $J_{1,2}$ = 9.2 Hz, H-1), 4.49 (1H, dd, $J_{5,6b}$ = 5.3 Hz, H-6b), 4.26–4.22 (1H, m, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 176.0 (CS), 166.0, 165.2, 165.2, 164.9 (CO), 138.1 (CH=N), 137.6–124.5 (Ar), 76.0, 76.1, 74.1, 69.33, 69.1 (C-1 to C-5), 62.8 (C-6). Anal. Calcd for $C_{42}H_{35}N_3O_9S$ (757.81): C, 66.57, H, 4.66; N, 5.54; S, 4.23. Found: C, 66.63; H, 4.72; N, 5.58; S, 4.29.

4.5. 2-Phenylamino-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-oxadiazole (10)

Semicarbazone **3** (0.20 g, 0.27 mmol) was dissolved in glacial AcOH (3 mL). Then $Pb(OAc)_4$ (0.18 g, 0.40 mmol) was added, and the mixture was stirred and heated at 70 °C. The reaction was monitored by TLC (1:2 EtOAc/hexane). When the reaction was complete, the reaction mixture was diluted with H_2O (15 mL), and extracted with EtOAc (3 × 6 ml). The organic phase was dried ($MgSO_4$), and evaporated under reduced pressure. The crude product was purified by column chromatography (1:2 EtOAc/hexane) to yield 90 mg (45%) of **10** as a white amorphous product. $[\alpha]_D$ = −17 (*c* 0.21, $CHCl_3$); R_f: 0.41 (1:2 EtOAc/hexane); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.87 (1H, s, NH), 8.02–7.00 (25H, m, Ar), 6.08, 5.93, 5.83 (3H, 3 pt, J = 9.5, 9.7 Hz in each, H-2, H-3, H-4), 5.13 (1H, d, $J_{1,2}$ = 9.9 Hz, H-1), 4.65 (1H, dd, $J_{5,6a}$ = 2.0 Hz, $J_{6a,6b}$ = 12.4 Hz, H-6a), 4.51 (1H, dd, $J_{5,6b}$ = 5.2 Hz, H-6b) 4.40–4.30 (1H, m, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.1, 165.7, 165.1, 164.9 (CO), 161.2, 154.8 (C-oxadiazole), 137.4–117.8 (Ar), 76.8, 73.6, 71.9, 70.1, 69.1 (C-1 to C-5), 63.0 (C-6). Anal. Calcd for $C_{42}H_{33}N_3O_{10}$ (739.73): C, 68.19, H, 4.50; N, 5.68. Found: C, 68.25; H, 4.59; N, 5.61.

4.6. General procedure I for the synthesis of O-perbenzoylated 4-acyl-[C-(β-D-glucopyranosyl)formaldehyde]semicarbazones

C-(2,3,4,6-Tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde semicarbazone[18] (**2**, 0.10 g, 0.15 mmol) was dissolved in dry CH_2Cl_2 (5 mL), and then Et_3N (0.063 mL, 0.45 mmol) and RCOCl (0.45 mmol) were added. The mixture was stirred and heated at 40 °C. The reaction was monitored by TLC (1:1 EtOAc/hexane). When the reaction was complete, the solvent was evaporated, and the residue was purified by column chromatography.

4.6.1. 4-Acetyl-[*C*-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde]semicarbazone (12)

From **2** (0.19 g, 0.29 mmol) and AcCl (62 μL, 0.87 mmol) according to General procedure I (Section 4.6). Purified by column chromatography (1:1.5 EtOAc/hexane) to yield 91 mg (47%) of **12** as a yellow amorphous product. $[\alpha]_D$ = +8 (*c* 0.35, $CHCl_3$); R_f: 0.37 (1:1 EtOAc/hexane); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 9.83 (1H, s, NH), 8.10–7.80 (8H, m, Ar), 7.58–7.18 (14H, m, Ar, CH=N, NH), 6.00, 5.73, 5.66 (3H, 3 pt, *J* = 9.6, 9.7 Hz in each, H-2, H-3, H-4), 4.65 (1H, dd, $J_{5,6a}$ = 1.8 Hz, $J_{6a,6b}$ = 12.2 Hz, H-6a), 4.52–4.37 (2H, m, H-1, H-6b), 4.28–4.17 (1H, m, H-5), 1.91 (3H, s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 173.8, 166.1, 165.8, 165.3, 165.1, 158.4 (CO, NHCO, NHCONH), 140.5 (CH=N), 133.4–128.2 (Ar), 77.7, 76.2, 73.7, 70.2, 69.3 (C-1 to C-5), 63.0 (C-6), 19.7 (CH_3). Anal. Calcd for $C_{38}H_{33}N_3O_{11}$ (707.68): C, 64.49, H, 4.70; N, 5.94. Found: C, 64.59; H, 4.79; N, 5.86.

4.6.2. 4-Benzoyl-[C-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde]semicarbazone (13)

From **2** (0.10 g, 0.15 mmol) and BzCl (53 μL, 0.45 mmol) according to General procedure I (Section 4.6). Purified by column chromatography (1:1.5 EtOAc/hexane) to yield 81 mg (70%) of **13** as a yellow amorphous product. $[\alpha]_D$ = −61 (*c* 0.18, $CHCl_3$); R_f: 0.51 (1:1 EtOAc/hexane); ^{1}H NMR (CD_3CN, 360 MHz) δ (ppm) 10.28 (1H, br s, NH), 8.06–7.30 (27H, m, Ar, CH=N, NH), 6.06, 5.80, 5.73 (3H, 3 pt, *J* = 9.5, 9.8 Hz in each, H-2, H-3, H-4), 4.70–4.65 (1H, m, H-5), 4.59 (2H, dd, $J_{5,6a}$ = 2.4 Hz, $J_{6a,6b}$ = 12.5 Hz, H-6a), 4.53 (1H, dd, $J_{5,6b}$ = 4.1 Hz, H-6b), 4.42 (1H, d, $J_{1,2}$ = 9.1 Hz, H-1). ^{13}C NMR (CD_3CN, 360 MHz) δ (ppm) 166.7, 166.4, 166.1, 166.0, 164.5 (CO, NHCO, NHCONH), 145.9 (CH=N) 134.5–118.2 (Ar), 78.6, 76.5, 75.1, 71.5, 70.0 (C-1 to C-5), 63.7 (C-6). Anal. Calcd for $C_{43}H_{35}N_3O_{11}$ (769.75): C, 67.09, H, 4.58; N, 5.46. Found: C, 67.01; H, 4.50; N, 5.55.

4.6.3. 4-(2-Naphthoyl)-[C-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde]semicarbazone (14)

From **2** (0.20 g, 0.30 mmol) and 2-naphthoyl chloride (172 mg, 0.90 mmol) according to General procedure I (Section 4.6). Purified by column chromatography (1:3,5 EtOAc/toluene) to yield 123 mg (50%) of **14** as a yellow amorphous product. $[\alpha]_D$ = −134 (*c* 0.16, $CHCl_3$); R_f: 0.43 (1:3.5 EtOAc/toluene); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 9.79 (1H, br s, NH), 8.18–7.23 (29H, m, Ar, CH=N, NH), 6.06, 5.77, 5.65 (3H, 3 pt, *J* = 8.7 Hz, 9.3 Hz in each, H-2, H-3, H-4), 4.73–4.58 (2H, m, H-1, H-6a), 4.48 (1H, dd, $J_{5,6b}$ = 4.9 Hz, $J_{6a,6b}$ = 12.1 Hz, H-6b), 4.32–4.19 (1H, m, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.1, 165.7, 165.3, 164.3 (CO, NHCO, NHCONH), 145.1 (CH=N), 134.8–123.8 (Ar), 78.5, 76.3, 73.6, 70.8, 69.4 (C-1 to C-5), 63.2 (C-6). Anal. Calcd for $C_{47}H_{37}N_3O_{11}$ (819.81): C, 68.86, H, 4.55; N, 5.13. Found: C, 68.97; H, 4.65; N, 5.20.

4.6.4. 4-(4-*tert*-Butylbenzoyl)-[C-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde]semicarbazone (15)

From **2** (0.10 g, 0.15 mmol) and 4-*tert*-butylbenzoyl chloride (88 μL, 0.45 mmol) according to General procedure I (Section 4.6). Purified by column chromatography (1:2 EtOAc/hexane) to yield 68 mg (55%) of **15** as a yellow amorphous product. $[\alpha]_D$ = +41 (*c* 0.52, $CHCl_3$); R_f: 0.27 (1:2 EtOAc/hexane); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 9.66 (1H, br s, NH), 8.01–7.21 (26H, m, Ar, CH=N, NH), 6.06, 5.77, 5.64 (3H, 3 pt, *J* = 8.6, 9.3 Hz in each, H-2, H-3, H-4), 4.76–4.56 (2H, m, H-1, H-6a), 4.49 (1H, dd, $J_{5,6b}$ = 4.9 Hz, $J_{6a,6b}$ = 12.1 Hz, H-6b), 4.32–4.18 (1H, m, H-5), 1.26 (9H, s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.0, 165.9, 165.6, 165.2 (CO, NHCO, NHCONH), 144.6 (CH=N), 155.4, 133.4–125.2 (Ar), 78.6, 76.2, 73.6, 70.8, 69.3 (C-1 to C-5), 63.2 (C-6), 34.7 (*C*tBu), 30.9 (CH_3). Anal. Calcd for $C_{47}H_{43}N_3O_{11}$ (825.86): C, 68.35, H, 5.25; N, 5.09. Found: C, 68.44; H, 5.36; N, 5.16.

4.7. General procedure II for the synthesis of 4-acyl-2-acylamino-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazolines

C-(2,3,4,6-Tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde thiosemicarbazone (**4**, 0.10 g, 0.14 mmol) was dissolved in dry pyridine (5 mL) and then RCOCl (0.44 mmol) was added. The mixture was stirred and heated at 80 °C. The reaction was monitored by TLC (1:2 EtOAc/hexane). When the reaction was complete, the solvent was evaporated, and the residue was purified by column chromatography.

4.7.1. 2-Acetamido-4-acetyl-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazoline (16)

From **4** (0.20 g, 0.28 mmol) and AcCl (60 μL, 0.84 mmol) according to General procedure II (Section 4.7). Purified by column chromatography (1:2 EtOAc/toluene) to yield 170 mg (77%) of **16** as a white amorphous product. $[\alpha]_D$ = −178 (*c* 0.35, $CHCl_3$); R_f: 0.30 (1:2 EtOAc/toluene); ESI-MS (positive mode) *m/z*: 766.25 $[M+H]^+$. Anal. Calcd for $C_{40}H_{35}N_3O_{11}S$ (765.78): C, 62.74, H, 4.61; N, 5.49; S, 4.19. Found: C, 62.71; H, 4.65; N, 5.46; S, 4.15.

major isomer: ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 9.43 (1H, s, NH), 8.10–7.11 (20H, m, Ar), 6.05–5.96 (2H, m, H-2 or H-3 or H-4, CH-thiadiazoline), 5.68, 5.56 (2H, 2 pt, *J* = 9.8 Hz in each, H-2 and/or H-3 and/or H-4), 4.53–4.42 (3H, m, H-6a, H-6b, H-1), 4.15–4.08 (1H, m, H-5), 1.99, 1.93 (6H, 2 s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 169.0, 166.0, 165.6, 165.0 (CO, NHCO), 147.4 (Cq-thiadiazoline), 133.6–125.1 (Ar), 76.0, 75.2, 73.5, 69.1, 66.3 (C-1 to C-5), 69.1 (CH-thiadiazoline), 62.4 (C-6), 22.6, 21.5 (CH_3).

Minor isomer: ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 9.14 (1H, s, NH), 5.84, 5.43 (2H, 2 pt, *J* = 9.5, 9.7 Hz in each, H-2 and/or H-3 and/or H-4).

4.7.2. 2-Benzamido-4-benzoyl-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazoline (17)

From **4** (0.50 g, 0.74 mmol) and BzCl (258 μL, 2.22 mmol) according to General procedure II (Section 4.7). Purified by column chromatography (1:2 EtOAc/hexane) to yield 400 mg (62%) of **17** as a yellow amorphous product. $[\alpha]_D$ = −295 (*c* 0.16, $CHCl_3$); R_f: 0.34 (1:2 EtOAc/hexane). ESI-MS (positive mode) *m/z*: 890.33 $[M+H]^+$. Anal. Calcd for $C_{50}H_{39}N_3O_{11}S$ (889.92): C, 67.48, H, 4.42; N, 4.72; S, 3.60. Found: C, 67.42; H, 4.45; N, 5.71; S, 3.63.

major isomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ (ppm) 9.26 (1H, s, NH) 8.05–7.10 (30H, m, Ar), 6.34 (1H, s, CH-thiadiazoline), 6.02 (1H, pt, *J* = 9.5 Hz, H-2 or H-3 or H-4), 5.72–5.60 (2H, m, H-2 and/or H-3 and/or H-4), 4.62 (1H, d, $J_{1,2}$ = 9.7 Hz, H-1), 4.54 (1H, dd, $J_{5,6a}$ = 5.3 Hz, $J_{6a,6b}$ = 12.3 Hz, H-6a), 4.48 (1H, dd, $J_{5,6b}$ = 1.9 Hz, H-6b), 4.17–4.11 (1H, m, H-5). ^{13}C NMR ($CDCl_3$, 400 MHz) δ (ppm) 166.6, 166.2, 165.7, 165.7, 165.1, 165.0 (CO, NHCO), 148.4 (Cq-thiadiazoline) 133.7–127.3 (Ar), 76.5, 75.9, 73.7, 69.2, 67.7 (C-1 to C-5), 69.1 (CH-thiadiazoline), 62.6 (C-6).

Minor isomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ (ppm) 9.10 (1H, s, NH), 6.63 (1H, s, CH-thiadiazoline), 6.09, 5.90 (2H, 2 pt, *J* = 9.5 Hz in each, H-2 and/or H-3 and/or H-4), 4.72 (1H, d, $J_{1,2}$ = 9.1 Hz,

H-1), 4.67 (1H, dd, $J_{5,6a}$ = 2.3 Hz, $J_{6a,6b}$ = 12.4 Hz, H-6a), 4.41 (1H, dd, $J_{5,6b}$ = 4.9 Hz, H-6b), 4.26–4.20 (1H, m, H-5). ^{13}C NMR ($CDCl_3$, 400 MHz) δ (ppm) 76.1, 74.8, 68.6 (C-1 to C-5), 60.3 (C-6).

4.7.3. 2-(2-Naphthamido)-4-(2-naphtoyl)-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazoline (18)

From **4** (0.50 g, 0.74 mmol) and 2-naphthoyl chloride (423 mg, 2.22 mmol) according to General procedure II (Section 4.7). Purified by column chromatography (1:2 EtOAc/hexane) to yield 450 mg (62%) of **18** as a yellow amorphous product. $[\alpha]_D$ = –318 (*c* 0.16, $CHCl_3$); R_f: 0.43 (1:8 EtOAc/toluene). ESI-MS (positive mode) *m/z*: 990.33 $[M+H]^+$. Anal. Calcd for $C_{58}H_{43}N_3O_{11}S$ (989.26): C, 70.36, H, 4.38; N, 4.24; S, 3.24. Found: C, 70.32; H, 4.36; N, 4.21; S, 3.27.

Major isomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ (ppm) 9.30 (1H, s, NH) 8.36–6.84 (34H, m, Ar), 6.36 (1H, d, CH-thiadiazoline), 5.96 (1H, pt, *J* = 9.5 Hz, H-2 or H-3 or H-4), 5.70–5.61 (2H, m, H-2 and/or H-3 and/or H-4), 4.60 (1H, dd, $J_{1,CH}$ = 1.4 Hz, $J_{1,2}$ = 9.9 Hz, H-1), 4.52 (1H, dd, $J_{6a,6b}$ = 12.2 Hz, H-6a,), 4.46 (1H, dd, H-6b), 3.97 (1H, ddd, $J_{5,6b}$ = 2.7 Hz, $J_{5,6a}$ = 4.9 Hz, $J_{4,5}$ = 9.7 Hz, H-5). ^{13}C NMR ($CDCl_3$, 400 MHz) δ (ppm) 169.7, 166.5, 166.3, 165.8, 165.7, 165.0 (CO, NHCO), 148.1 (Cq-thiadiazoline), 135.3–123.5 (Ar), 76.4, 75.8, 73.7, 69.1, 68.0 (C-1 to C-5), 69.1 (CH-thiadiazoline), 62.5 (C-6).

Minor isomer: ^{1}H NMR ($CDCl_3$, 400 MHz) δ (ppm) 6.68 (1H, d, CH-thiadiazoline), 6.13, 5.89 (2H, 2 pt, *J* = 9.5 Hz in each, H-2 and/or H-3 and/or H-4), 4.76 (1H, dd, $J_{1,CH}$ = 2.5 Hz, $J_{1,2}$ = 9.8 Hz, H-1), 4.65 (1H, dd, $J_{6a,6b}$ = 12.3 Hz, H-6a), 4.19 (1H, ddd, $J_{5,6a}$ = 2.8 Hz, $J_{5,6b}$ = 4.6 Hz, $J_{4,5}$ = 9.6 Hz, H-5). ^{13}C NMR ($CDCl_3$, 400 MHz) δ (ppm) 167.3, 166.2, 165.4, 164.9 (CO, NHCO), 148.7 (Cq-thiadiazoline), 76.1, 75.4, 74.8, 68.5, 67.8 (C-1 to C-5), 63.0 (C-6).

4.7.4. 2-(4-*tert*-Butylbenzamido)-4-(4-*tert*-butylbenzoyl)-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-Δ^2-1,3,4-thiadiazoline (19)

From **4** (0.15 g, 0.22 mmol) and 4-*tert*-butylbenzoyl chloride (129 μL, 0.66 mmol) according to General procedure II (Section 4.7). Purified by column chromatography (1:4 EtOAc/hexane) to yield 83 mg (38%) of **19** as a yellow amorphous product. $[\alpha]_D$ = –378 (*c* 0.18, $CHCl_3$); R_f: 0.48 (1:2 EtOAc/hexane); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.71 (1H, s, NH), 8.01–7.14 (28H, m, Ar), 6.36 (1H, d, *J* = 1.4 Hz, CH-thiadiazoline), 6.01, 5.65, 5.64 (3H, 3 pt, *J* = 9.5 Hz in each, H-2, H-3, H-4), 4.64–4.55 (2H, m, H-6a, H-1), 4.42 (1H, dd, $J_{6a,6b}$ = 12.0 Hz, H-6b), 4.14 (1H, ddd, $J_{5,6b}$ = 2.0 Hz, $J_{5,6a}$ = 5.7 Hz, $J_{4,5}$ = 9.5 Hz, H-5), 1.36 (9H, br s, CH_3), 1.31 (9H, s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.4, 166.3, 165.8, 165.8, 165.2, 164.7 (CO, NHCO), 156.9, 154.3 (Cq-phenyl), 145.9 (Cq-thiadiazoline), 133.7–124.7 (Ar), 76.6, 76.0, 73.8, 69.3, 67.8, (C-1 to C-5), 69.1 (CH-thiadiazoline), 62.8 (C-6), 35.2, 34.9 (Cq), 31.2, 31.1 (CH_3). ESI-MS (positive mode) *m/z*: 1002.33 $[M+H]^+$. Anal. Calcd for $C_{58}H_{55}N_3O_{11}S$ (1002.14): C, 69.51, H, 5.53; N, 4.19; S, 3.20. Found: C, 69.54; H, 5.56; N, 4.16; S, 3.25.

4.8. General procedure III for the synthesis of 2-acylamino-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-oxadiazoles and -thiadiazoles

A 4-acyl-[*C*-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)formaldehyde]semicarbazone (**12–15**, 0.03 mmol) or a 2-acylamino-4-acyl-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-thiadiazoline (**16–19**, 0.03 mmol) was dissolved in CH_2Cl_2 (1 mL). Then PIDA (1.1 equiv) was added, and the mixture was stirred at room temperature. The reaction was monitored by TLC (1:1 EtOAc/hexane). When the reaction was complete, the solvent was evaporated and the residue was purified by column chromatography.

4.8.1. 2-Acetamido-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-oxadiazole (20)

From **12** (0.16 g, 0.23 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:3 EtOAc/hexane) to yield 81 mg (50%) of **20** as a white amorphous product. $[\alpha]_D$ = –2 (*c* 0.25, $CHCl_3$); R_f: 0.38 (1:3 EtOAc/toluene); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.03–7.22 (21H, m, Ar, NH), 6.08, 5.86, 5.84 (3H, 3 pt, *J* = 9.7 Hz in each H-2, H-3, H-4), 5.18 (1H d, $J_{1,2}$ = 9.8 Hz, H-1), 4.71–4.60 (1H, dd, $J_{5,6a}$ < 1 Hz, H-6a), 4.52 (1H, dd, $J_{5,6b}$ = 4.3 Hz, $J_{6a,6b}$ = 12.1 Hz, H-6b), 4.40–4.30 (1H, m, H-5), 2.53 (1H, s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.0, 165.6, 165.2, 165.0, 164.8, 160.9 (CO, NHCO, C-oxadiazole), 133.5–128.3 (Ar), 76.9, 73.4, 71.8, 70.3, 68.9 (C-1 to C-5), 62.9 (C-6), 11.0 (CH_3). Anal. Calcd for $C_{38}H_{31}N_3O_{11}$ (705.67): C, 64.68, H, 4.43; N, 5.95. Found: C, 64.60; H, 4.51; N, 5.86.

4.8.2. 2-Benzamido-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-oxadiazole (21)

From **13** (0.084 g, 0.11 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:3 EtOAc/hexane) to yield 70 mg (57%) of **21** as a white amorphous product. $[\alpha]_D$ = –205 (*c* 0.4, $CHCl_3$); R_f: 0.68 (1:1 EtOAc/hexane); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.06–7.26 (26H, m, Ar, NH), 6.11, 6.02, 5.88 (3H, 3 pt, *J* = 9.5, 9.8 Hz in each H-2, H-3, H-4), 5.28 (1H d, $J_{1,2}$ = 9.8 Hz, H-1), 4.71 (1H, dd, $J_{6a,6b}$ = 12.4 Hz, H-6a), 4.54 (1H, dd, H-6b) 4.39 (1H, ddd, $J_{5,6a}$ = 2.4 Hz, $J_{5,6b}$ = 5.2 Hz, $J_{4,5}$ = 9.4 Hz, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.0, 165.9, 165.6, 165.1, 164.8, 160.9 (CO, NHCO, C-oxadiazole), 133.5–123.3 (Ar), 77.0, 73.5, 71.8, 70.2, 69.0 (C-1 to C-5), 62.9 (C-6). Anal. Calcd for $C_{43}H_{33}N_3O_{11}$ (767.74): C, 67.27, H, 4.33; N, 5.47. Found: C, 67.35; H, 4.42; N, 5.40.

4.8.3. 2-(2-Naphthamido)-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-oxadiazole (22)

From **14** (0.28 g, 0.34 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:6 EtOAc/toluene) to yield 192 mg (69%) of **22** as a yellow amorphous product. $[\alpha]_D$ = –121 (*c* 0.16, $CHCl_3$); R_f: 0.58 (1:3.5 EtOAc-toluene); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.52 (1H, s, NH), 8.11–7.10 (27H, m, Ar), 6.18, 6.11, 5.95 (3H, 3 pt, *J* = 9.7 Hz in each, H-2, H-3, H-4), 5.27 (1H, d, $J_{1,2}$ = 9.5 Hz, H-1), 4.70 (1H, dd, $J_{6a,6b}$ = 12.4 Hz, H-6a), 4.54 (1H, dd, H-6b) 4.39 (1H, ddd, $J_{5,6a}$ = 2.7 Hz, $J_{5,6b}$ = 4.3 Hz, $J_{4,5}$ = 9.5 Hz, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.0, 165.9, 165.6, 164.8, 161.1 (CO, NHCO, C-oxadiazole), 134.7–120.5 (Ar), 77.0, 73.6, 71.9, 70.3, 69.1 (C-1 to C-5), 63.0 (C-6). Anal. Calcd for $C_{47}H_{35}N_3O_{11}$ (817.79): C, 69.03, H, 4.31; N, 5.14. Found: C, 69.11; H, 4.41; N, 5.05.

4.8.4. 2-(4-*tert*-Butylbenzamido)-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-oxadiazole (23)

From **15** (0.09 g, 0.11 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:3 EtOAc/hexane) to yield 80 mg (60%) of **23** as a colourless amorphous product. $[\alpha]_D$ = –82 (*c* 1.50, $CHCl_3$); R_f: 0.29 (1:3 EtOAc/hexane); ^{1}H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.05–7.20 (25H, m, Ar, NH), 6.11, 6.02, 5.88 (3H, 3 pt, *J* = 9.5, 9.7 Hz in each, H-2, H-3, H-4), 5.28 (1H, d, $J_{1,2}$ = 9.7 Hz, H-1), 4.70 (1H, dd, $J_{6a,6b}$ = 12.4 Hz, H-6a), 4.54 (1H, dd, H-6b), 4.40 (1H, ddd, $J_{5,6a}$ = 2.3 Hz, $J_{5,6b}$ = 5.3 Hz, $J_{4,5}$ = 9.7 Hz, H-5), 1.34 (9H, s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.0, 165.9, 165.6, 165.1, 164.8, 161.1 (CO, NHCO, C-oxadiazole), 155.6, 133.5–120.5 (Ar), 77.0, 73.6, 71.8, 70.2, 69.1 (C-1 to C-5), 63.0 (C-6), 35.0 (Cq-*t*Bu), 31.0 (CH_3). Anal. Calcd for $C_{47}H_{41}N_3O_{11}$

(823.84): C, 68.52, H, 5.02; N, 5.10. Found: C, 68.61; H, 5.11; N, 5.18.

4.8.5. 2-Acetamido-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-thiadiazole (24)

From **16** (0.17 g, 0.22 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:2 EtOAc/toluene) to yield 106 mg (67%) of **24** as a white amorphous product. $[\alpha]_D = -81$ (*c* 0.25, $CHCl_3$); R_f: 0.42 (1:2 EtOAc/toluene); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.09–7.13 (21H, m, Ar, NH), 6.09, 5.81, 5.74 (3H, 3 pt, $J = 9.6$, 9.8 Hz in each, H-2, H-3, H-4), 5.25 (1H, d, $J_{1,2} = 9.6$ Hz, H-1), 4.70 (1H, dd, $J_{6a,6b} = 12.3$ Hz, H-6a), 4.53 (1H, dd, H-6b), 4.36 (1H, ddd, $J_{5,6a} = 3.0$ Hz, $J_{5,6b} = 4.8$ Hz, $J_{4,5} = 9.5$ Hz, H-5), 1.82 (3H, s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 168.8, 166.1, 165.7, 165.1, 164.7 (CO, NHCO, C-thiadiazole), 133.5–128.4 (Ar), 76.9, 76.0, 73.5, 71.7, 69.2 (C-1 to C-5), 62.9 (C-6). ESI-MS (positive mode) *m/z*: 722.33 $[M+H]^+$. Anal. Calcd for $C_{38}H_{31}N_3O_{10}S$ (721.76): C, 63.24, H, 4.33; N, 5.82; S,4.44. Found: C, 63.21; H, 4.35; N, 5.84; S, 4.41.

4.8.6. 2-Benzamido-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-thiadiazole (25)

From **17** (0.09 g, 0.10 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:3 EtOAc/hexane) to yield 54 mg (68%) of **25** as a white amorphous product. $[\alpha]_D = -111$ (*c* 0.20, $CHCl_3$); R_f: 0.21 (1:2 EtOAc/hexane); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.20–7.26 (26H, m, Ar, NH), 6.12, 5.86, 5.77 (3H, 3 pt, $J = 9.5$, 9.8 Hz in each, H-2, H-3, H-4), 5.32 (1H, d, $J_{1,2} = 9.7$ Hz, H-1), 4.70 (1H, dd, $J_{6a,6b} = 12.4$ Hz, H-6a), 4.55 (1H, dd, H-6b) 4.40 (1H, ddd, $J_{5,6a} = 2.7$ Hz, $J_{5,6b} = 5.0$ Hz, $J_{4,5} = 9.7$ Hz, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.2, 165.7, 165.1, 165.0, 164.9, 162.5, 161.1 (CO, NHCO, C-thiadiazole), 133.3–128.3 (Ar), 77.0, 76.3, 73.6, 72.2, 69.2, (C-1 to C-5), 63.1 (C-6). Anal. Calcd for $C_{43}H_{33}N_3O_{10}S$ (783.8): C, 65.89, H, 4.24; N, 5.36; S,4.09. Found: C, 65.94; H, 4.35; N, 5.28; S, 4.01.

4.8.7. 2-(2-Naphthamido)-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-thiadiazole (26)

From **18** (0.20 g, 0.20 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:6 EtOAc/toluene) to yield 100 mg (59%) of **26** as a yellow amorphous product. $[\alpha]_D = -205$ (*c* 0.16, $CHCl_3$); R_f: 0.39 (1:6 EtOAc/toluene); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.71 (s, 1H, NH), 8.12–7.11 (27H, m, Ar), 6.15, 5.91, 5.80 (3H, 3pt, $J = 9.6$ Hz in each, H-2, H-3, H-4), 5.35 (1H, d, $J_{1,2} = 9.7$ Hz, H-1), 4.70 (1H, dd, $J_{6a,6b} = 12.3$ Hz, H-6a), 4.57 (1H, dd, H-6b), 4.41 (1H, ddd, $J_{5,6a} = 2.0$ Hz, $J_{5,6b} = 4.9$ Hz, $J_{4,5} = 9.4$ Hz, H-5). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.1, 165.7, 165.2, 165.1, 165.0, 162.5, 160.9 (CO, NHCO, C-thiadiazole), 135.5–124.2 (Ar), 76.9, 76.3, 73.6, 72.3, 69.3 (C-1 to C-5), 63.1 (C-6). ESI-MS (positive mode) *m/z*: 834.33 $[M+H]^+$. Anal. Calcd for $C_{47}H_{35}N_3O_{10}S$ (833.86): C, 67.70, H, 4.23; N, 5.04; S, 3.85. Found: C, 67.81; H, 4.15; N, 5.12; S, 3.76.

4.8.8. 2-(4-*tert*-Butylbenzamido)-5-(2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl)-1,3,4-thiadiazole (27)

From **19** (0.17 g, 0.17 mmol) according to General procedure III (Section 4.8). Purified by column chromatography (1:3 EtOAc/hexane) to yield 120 mg (84%) of **27** as a white amorphous product. $[\alpha]_D = -179$ (*c* 0.20, $CHCl_3$); R_f: 0.20 (1:3 EtOAc/hexane); ^1H NMR ($CDCl_3$, 360 MHz) δ (ppm) 8.05–7.22 (25H, m, Ar, NH), 6.12, 5.86, 5.80 (3H, 3 pt, $J = 9.5$, 9.7 Hz in each, H-2, H-3, H-4), 5.31 (1H, d, $J_{1,2} = 9.6$ Hz, H-1), 4.68 (1H, dd, $J_{5,6a} < 1$ Hz, $J_{6a,6b} = 12.2$ Hz, H-6a), 4.54 (1H, dd, $J_{5,6b} = 5.0$ Hz, H-6b), 4.43–4.35 (1H, m, H-5), 1.38 (9H, s, CH_3). ^{13}C NMR ($CDCl_3$, 360 MHz) δ (ppm) 166.1, 165.8, 165.2, 165.0, 164.8, 161.8, 160.9 (CO, NHCO, C-thiadiazole), 156.9, 133.5–125.8 (Ar), 76.9, 76.3, 73.7, 72.2, 69.4 (C-1 to C-5), 63.2 (C-6), 31.9 (Cq-*t*Bu), 31.1 (CH_3). ESI-MS (positive mode) *m/z*: 840.42 $[M+H]^+$. Anal. Calcd for $C_{47}H_{41}N_3O_{10}S$ (839.91): C, 67.21, H, 4.92; N, 5.00; S, 3.82. Found: C, 67.31; H, 4.83; N, 5.09; S, 3.91.

4.9. Preparation for the test compounds

4.9.1. General procedure IV for the Zemplén debenzoylation

An O-perbenzoylated compound (100 mg) was dissolved in dry MeOH (1 mL) and a solution of NaOMe (1 M in MeOH) was added to the solution in a catalytic amount. The reaction mixture was kept at rt. When the reaction was complete (TLC, 7:3 $CHCl_3$/MeOH) the solution was neutralized with a cation exchange resin Amberlyst 15 (H^+ form). The resin was filtered off with suction, the filtrate was evaporated under reduced pressure. The crude product was purified by column chromatography.

4.9.2. General procedure V for the removal of *O*-benzoyl protecting groups

An O-perbenzoylated compound (100 mg) was dissolved in dry MeOH (14 mL) and LiOH (16 equiv) was added. The reaction mixture was stirred at 0 °C. When the reaction was complete (TLC, 7:3 $CHCl_3$/MeOH) the solution was neutralized with a cation exchange resin Amberlyst 15 (H^+ form). After filtration and removal of the solvent, the residue was purified by column chromatography.

4.9.3. *C*-(β-D-Glucopyranosyl)formaldehyde semicarbazone (6)

From **2** (0.17 g, 0.26 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (8:5 $CHCl_3$/methanol) to yield 40 mg (63%) of **6** as a white amorphous product. $[\alpha]_D = +32$ (*c* 0.30, DMSO); R_f: 0.17 (2:1 $CHCl_3$/methanol); ^1H NMR (MeOD, 360 MHz) δ (ppm) 7.19 (1H, s, CH=N), 3.88–3.72 (2H, m, H-1, H-2 or H-3 or H-4), 3.70–3.52 (1H, m, H-6a), 3.50–3.22 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b). ^{13}C NMR (MeOD, 360 MHz) δ (ppm) 160.1 (NHCONH), 143.2 (CH=N), 81.8, 80.2, 79.4, 73.4, 71.4 (C-1 to C-5), 62.7 (C-6). Anal. Calcd for $C_{84}H_{15}N_3O_6$ (249.22): C, 38.55, H, 6.07; N, 16.86. Found: C, 38.63; H, 6.12; N, 16.93.

4.9.4. 4-Phenyl-[C-(β-D-glucopyranosyl)formaldehyde] semicarbazone (7)

From **3** (0.20 g, 0.27 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (4:1 $CHCl_3$/methanol) to yield 42 mg (48%) of **7** as a white amorphous product. $[\alpha]_D = +52$ (*c* 0.43, DMSO); R_f: 0.23 (4:1 $CHCl_3$/methanol); ^1H NMR (MeOD, 360 MHz) δ (ppm) 7.46 (2H, d, $J = 7.9$ Hz, Ar), 7.30–7.17 (3H, m, Ar, CH=N), 7.01 (1H, t, $J = 7.3$ Hz, Ar), 3.91–3.79 (2H, m, H-1, H-2 or H-3 or H-4), 3.65 (1H, dd, $J_{5,6a} = 4.5$ Hz, $J_{6a,6b} = 11.4$ Hz, H-6a), 3.42–3.21 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b), ^{13}C NMR (MeOD, 360 MHz) δ (ppm) 155.9 (NHCONH), 143.3 (CH=N), 139.7, 129.8, 124.5, 121.3 (Ar), 82.0, 80.2, 79.5, 73.5, 71.5 (C-1/C-5), 62.8 (C-6). Anal. Calcd for $C_{14}H_{19}N_3O_6$ (325.32): C, 51.69, H, 5.89; N, 12.92. Found: C, 51.79; H, 5.98; N, 12.85.

4.9.5. *C*-(β-D-glucopyranosyl)formaldehyde thiosemicarbazone (8)

From **4** (0.16 g, 0.24 mmol) according to General procedure V (Section 4.9.2). Purified by column chromatography (3:1 $CHCl_3$/methanol) to yield 60 mg (95%) of **8** as a white amorphous product. $[\alpha]_D = +6$ (*c* 2.00, DMSO); R_f: 0.24 (3:1 $CHCl_3$/methanol); ^1H NMR (MeOD, 360 MHz) δ (ppm) 7.39 (1H, s, CH=N), 3.92–3.81 (2H, m, H-1, H-2 or H-3 or H-4), 3.68 (1H, dd, $J_{5,6a} = 3.1$ Hz, $J_{6a,6b} = 10.9$ Hz, H-6a), 3.52–3.32 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b). ^{13}C NMR (MeOD, 360 MHz) δ (ppm) 180.0 (NHCSNH), 145.5 (CH=N), 81.7, 79.8, 79.0, 73.2, 71.4 (C-1/C-5), 62.7 (C-6). Anal. Calcd for $C_8H_{15}N_3O_5S$ (265.29): C, 36.22, H, 5.70; N, 15.84; S, 12.09. Found: C, 36.12; H, 5.81; N, 15.92; S, 12.17.

4.9.6. 4-Phenyl-[C-(β-D-glucopyranosyl)formaldehyde] thiosemicarbazone (9)

From **5** (0.20 g, 0.26 mmol) according to General procedure V (Section 4.9.2). Purified by column chromatography (7:1 $CHCl_3$/methanol) to yield 70 mg (77%) of **9** as a yellow amorphous product. $[\alpha]_D$ = +33 (*c* 0.13, MeOH); R_f: 0.40 (3:1 $CHCl_3$/methanol); ^1H NMR (MeOD, 360 MHz) δ (ppm) 7.61 (2H, d, J = 7.8 Hz, Ar), 7.42–7.30 (3H, m, Ar, CH=N), 7.21 (1H, t, J = 7.4 Hz, Ar), 3.97–3.82 (2H, m, H-1, H-2 or H-3 or H-4), 3.71 (1H, dd, $J_{5,6a}$ = 4.8 Hz, $J_{6a,6b}$ = 11.8 Hz, H-6a), 3.48–3.33 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b). ^{13}C NMR (MeOD, 360 MHz) δ (ppm) 178.3 (NHCSNH), 144.7 (CH=N), 140.1, 129.4, 126.8, 126.2 (Ar), 82.0, 80.1, 79.5, 73.4, 71.5 (C-1/C-5), 62.8 (C-6). Anal. Calcd for $C_{13}H_{19}N_3O_5S$ (341.38): C, 49.26, H, 5.61; N, 12.31; S, 9.39. Found: C, 49.19; H, 5.70; N, 12.39; S, 9.29.

4.9.7. 2-Phenylamino-5-(β-D-glucopyranosyl)-1,3,4-oxadiazole (11)

From **10** (0.16 g, 0.22 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (7:1 $CHCl_3$/methanol) to yield 68 mg (97%) of **11** as a white amorphous product. $[\alpha]_D$ = +14 (*c* 0.21, DMSO); R_f: 0.24 (7:1 $CHCl_3$/methanol); ^1H NMR (MeOD, 360 MHz) δ (ppm) 7.49 (2H, d, J = 8.0 Hz, Ar), 7.33 (2H, t, J = 7.6 Hz, Ar), 7.03 (1H, t, J = 7.3 Hz, Ar), 4.44 (1H, d, $J_{1,2}$ = 9.9 Hz, H-1), 3.93–3.85 (1H, m, H-6a), 3.77–3.65 (2H, m, H-2 or H-3 or H-4, H-6b), 3.55–3.37 (3H, m, H-2 and/or H-3 and/or H-4, H-5). ^{13}C NMR (MeOD, 360 MHz) δ (ppm) 162.4, 159.2 (C-oxadiazole), 139.6, 130.2, 123.8, 118.8 (Ar), 82.6, 79.1, 74.6, 73.2, 71.3 (C-1/C-5), 62.8 (C-6). Anal. Calcd for $C_{14}H_{17}N_3O_6$ (323.30): C, 52.01, H, 5.30; N, 13.00. Found: C, 52.11; H, 5.39; N, 13.11.

4.9.8. 2-Acetamido-5-(β-D-glucopyranosyl)-1,3,4-oxadiazole (28)

From **20** (0.18 g, 0.62 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (5:1 $CHCl_3$/methanol) to yield 30 mg (41%) of **28** as a white amorphous product. $[\alpha]_D$ = +38 (*c* 0.15, H_2O); R_f: 0.28 (3:1 $CHCl_3$/methanol); ^1H NMR (D_2O+MeOD, 360 MHz) δ (ppm) 4.69 (1H, d, $J_{1,2}$ = 9.9 Hz, H-1), 3.91 (1H, dd, $J_{5,6a}$ = 1.4 Hz, $J_{6a,6b}$ = 12.1 Hz, H-6a), 3.82–3.70 (2H, m, H-2 or H-3 or H-4, H-6b), 3.66–3.57 (2H, m, H-2 or H-3 or H-4, H-5), 3.52 (1H, pt, J = 9.2 Hz, H-2 or H-3 or H-4), 2.57 (3H, s, CH_3). ^{13}C NMR (D_2O+MeOD, 360 MHz) δ (ppm) 166.6 (NHCO, C-oxadiazole), 163.8 (C-oxadiazole), 80.4, 76.6, 72.3, 71.5, 69.2 (C-1 to C-5), 62.7 (C-6), 10.0 (CH_3). Anal. Calcd for $C_{10}H_{15}N_3O_7$ (289.24): C, 41.52, H, 5.23; N, 14.53. Found: C, 41.59; H, 5.29; N, 14.62.

4.9.9. 2-Benzamido-5-(β-D-glucopyranosyl)-1,3,4-oxadiazole (30)

From **21** (0.15 g, 0.43 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (8:1 $CHCl_3$/methanol) to yield 60 mg (87%) of **29** as a white amorphous product. $[\alpha]_D$ = +11 (*c* 0.13, DMSO); R_f: 0.26 (3:1 $CHCl_3$/methanol); ^1H NMR (MeOD, 360 MHz) δ (ppm) 8.07 (2H, d, J = 7.2 Hz, Ar), 7.65–7.50 (3H, m, Ar), 4.66 (1H d, $J_{1,2}$ = 9.8 Hz, H-1), 3.93 (1H, dd, $J_{5,6a}$ = 1.4 Hz, $J_{6a,6b}$ = 12.1 Hz, H-6a), 3.85 (1H, pt, J = 9.0 Hz, H-2 or H-3 or H-4), 3.74 (1H, dd, $J_{5,6b}$ = 5.2 Hz, H-6b) 3.60–3.43 (3H, m, H-2 and/or H-3 and/or H-4, H-5,). ^{13}C NMR (MeOD, 360 MHz) δ (ppm) 166.8 (NHCO, C-oxadiazole), 165.6 (C-oxadiazole), 133.4, 130.4, 128.0, 124.6 (Ar), 82.8, 79.0, 74.6, 73.4, 71.2 (C-1 to C-5), 62.7 (C-6). Anal. Calcd for $C_{15}H_{17}N_3O_7$ (351.31): C, 51.28, H, 4.88; N, 11.96. Found: C, 51.20; H, 4.93; N, 12.06.

4.9.10. 2-(2-Naphthamido)-5-(β-D-glucopyranosyl)-1,3,4-oxadiazole (30)

From **22** (0.16 g, 0.40 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (8:1 $CHCl_3$/methanol) to yield 73 mg (93%) of **30** as a white amorphous product. $[\alpha]_D$ = +13 (*c* 0.10, DMSO); R_f: 0.13 (8:1 $CHCl_3$/methanol); ^1H NMR (DMSO-d_6, 360 MHz) δ (ppm) 7.81 (1H, br s, Ar), 7.35–7.10 (4H, m, Ar), 6.82 (2H, br s, Ar), 3.87 (1H, d, $J_{1,2}$ = 9.6 Hz, H-1), 3.15–3.02 (2H, m, H-2 or H-3 or H-4, H-6a,), 2.97–2.87 (1H, m, H-6b), 2.80–2.64 (3H, m, H-2 and/or H-3 and/or H-4, H-5,). ^{13}C NMR (DMSO-d_6, 360 MHz) δ (ppm) 164.8 (NHCO, C-oxadiazole), 164.2 (C-oxadiazole), 134.4–120.5 (Ar), 81.9, 77.3, 72.9, 71.8, 69.9 (C-1/C-5), 61.0 (C-6). Anal. Calcd for $C_{19}H_{19}N_3O_7$ (401.37): C, 56.86, H, 4.77; N, 10.47. Found: C, 56.79; H, 4.88; N, 10.38.

4.9.11. 2-(4-*tert*-Butylbenzamido)-5-(β-D-glucopyranosyl)-1,3,4-oxadiazole (31)

From **23** (0.15 g, 0.37 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (7:1 $CHCl_3$/methanol) to yield 56 mg (76%) of **31** as a white amorphous product. $[\alpha]_D$ = +13 (*c* 0.29, DMSO); R_f: 0.30 (7:1 $CHCl_3$/methanol); ^1H NMR (MeOD, 360 MHz) δ (ppm) 7.99 (2H, d, J = 8.2 Hz, Ar), 7.62 (2H, d, J = 8.2 Hz, Ar), 4.66 (1H, d, $J_{1,2}$ = 9.8 Hz, H-1), 3.92 (1H, m, H-6a), 3.84 (1H, pt, J = 9.1 Hz, H-2 or H-3 or H-4), 3.72 (1H, dd, $J_{5,6b}$ = 4.6 Hz, $J_{6a,6b}$ = 12.0 Hz, H-6b), 3.62–3.42 (3H, m, H-2 and/or H-3 and/or H-4, H-5), 1.37 (9H, s, CH_3). ^{13}C NMR (MeOD, 360 MHz) δ (ppm) 167.0 (NHCO, C-oxadiazole), 165.4 (C-oxadiazole), 157.3, 127.9, 127.4, 121.8 (Ar), 82.9, 79.1, 74.6, 73.4, 71.3 (C-1 to C-5), 62.8 (C-6), 36.0 (Cq-*t*Bu), 31.5 (CH_3). Anal. Calcd for $C_{19}H_{25}N_3O_7$ (407.42): C, 56.01, H, 6.18; N, 10.31. Found: C, 56.12; H, 6.27; N, 10.21.

4.9.12. 2-Acetamido-5-(β-D-glucopyranosyl)-1,3,4-thiadiazole (32)

From **24** (0.18 g, 0.59 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (8:1 $CHCl_3$/methanol) to yield 70 mg (92%) of **32** as a white amorphous product. $[\alpha]_D$ = +25 (*c* 0.27, DMSO); R_f: 0.12 (8:1 $CHCl_3$/methanol); ^1H NMR (DMSO-d_6, 360 MHz) δ (ppm) 4.48 (1H, d, $J_{1,2}$ = 9.0 Hz, H-1), 3.69 (1H, dd, $J_{5,6a}$ = 4.8 Hz, $J_{6a,6b}$ = 11.6 Hz, H-6a), 3.47–3.27 (4H, m, H-2, H-3, H-4, H-6b), 3.22–3.18 (1H, m, H-5), 2.19 (3H, s, CH_3). ^{13}C NMR (DMSO-d_6, 360 MHz) δ (ppm) 168.5 (NHCO), 162.8, 158.9 (C-thiadiazole), 81.5, 77.6, 76.7, 74.5, 69.9 (C-1 to C-5), 61.1 (C-6), 22.3 (CH_3). Anal. Calcd for $C_{10}H_{15}N_3O_6S$ (305.31): C, 39.34, H, 4.95; N, 13.76; S, 10.50. Found: C, 39.25; H, 4.86; N, 13.65; S, 10.59.

4.9.13. 2-Benzamido-5-(β-D-glucopyranosyl)-1,3,4-thiadiazole (33)

From **25** (0.11 g, 0.30 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (8:1 $CHCl_3$/methanol) to yield 35 mg (68%) of **33** as a white amorphous product. $[\alpha]_D$ = +9 (*c* 0.20, DMSO); R_f: 0.13 (8:1 $CHCl_3$/methanol); ^1H NMR (DMSO-d_6, 360 MHz) δ (ppm) 8.09 (2H, d, J = 7.5 Hz, Ar), 7.66 (1H, pt, J = 7.2 Hz, Ar), 7.56 (2H, pt, J = 7.5 Hz, Ar), 4.54 (1H, d, $J_{1,2}$ = 8.7 Hz, H-1), 3.76–3.66 (1H, m, H-6a), 3.45 (1H, dd, $J_{5,6b}$ = 6.0 Hz, $J_{6a,6b}$ = 11.9 Hz, H-6b), 3.40–3.29 (3H, m, H-2 and/or H-3 and/or H-4, H-5), 3.20 (1H, t, J = 8.7 Hz, H-2 or H-3 or H-4). ^{13}C NMR (DMSO-d_6, 360 MHz) δ (ppm) 165.5 (NHCO), 163.4, 160.2 (C thiadiazole), 133.2, 131.6, 128.9, 128.5 (Ar), 81.7, 77.6, 76.9, 74.6, 70.0 (C-1 to C-5), 61.2 (C-6). ESI-MS (positive mode) *m/z*: 368.08 $[M+H]^+$. Anal. Calcd for $C_{15}H_{17}N_3O_6S$ (367.38): C, 49.04, H, 4.66; N, 11.44; S, 8.73. Found: C, 49.13; H, 4.75; N, 11.53; S, 8.62.

4.9.14. 2-(2-Naphthamido)-5-(β-D-glucopyranosyl)-1,3,4-thiadiazole (34)

From **26** (0.14 g, 0.34 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (7:1 $CHCl_3$/methanol) to yield 40 mg (57%) of **34** as a white amorphous product. $[\alpha]_D$ = +10 (*c* 1.10, DMSO); R_f: 0.32 (7:1 $CHCl_3$/methanol); ^1H NMR (DMSO-d_6, 360 MHz) δ (ppm) 8.81 (1H, br s, Ar), 8.15–8.00 (4H, m, Ar), 7.72–7.60 (2H, m, Ar), 4.55 (1H, d, $J_{1,2}$ = 8.9 Hz, H-1), 3.76–3.68 (1H, m, H-6a), 3.40–3.30 (4H, m, H-2 and/or H-3 and/or H-4, H-5, H-6b), 3.21 (1H, pt, *J* = 8.9 Hz, H-2 or H-3 or H-4). ^{13}C NMR (DMSO-d_6, 360 MHz) δ (ppm) 165.5 (NHCO), 163.2, 160.0 (C-thiadiazole), 134.9–122.8 (Ar), 81.6, 77.6, 76.8, 74.5, 69.9 (C-1 to C-5), 61.1 (C-6). Anal. Calcd for $C_{19}H_{19}N_3O_6S$ (417.44): C, 54.67, H, 4.59; N, 10.07; S, 7.68. Found: C, 54.56; H, 4.68; N, 10.01; S, 7.78.

4.9.15. 2-(4-*tert*-Butylbenzamido)-5-(β-D-glucopyranosyl)-1,3,4-thiadiazole (35)

From **27** (0.18 g, 0.43 mmol) according to General procedure IV (Section 4.9.1). Purified by column chromatography (7:1 $CHCl_3$/methanol) to yield 60 mg (66%) of **35** as a white amorphous product. $[\alpha]_D$ = +9 (*c* 1.00, DMSO); R_f: 0.36 (7:1 $CHCl_3$/methanol); ^1H NMR (DMSO-d_6, 360 MHz) δ (ppm) 8.07 (2H, d, *J* = 8.2 Hz, Ar), 7.59 (2H, d, *J* = 8.2 Hz, Ar), 4.55 (1H, d, $J_{1,2}$ = 8.6 Hz, H-1), 3.78–3.70 (1H, m, H-6a), 3.48 (1H, dd, $J_{5,6b}$ = 5.9 Hz, $J_{6a,6b}$ = 11.8 Hz, H-6b), 3.41–3.30 (3H, m, H-2 and/or H-3 and/or H-4, H-5), 3.22 (1H, pt, *J* = 8.7 Hz, H-2 or H-3 or H-4), 1.33 (9H, s, CH_3). ^{13}C NMR (DMSO-d_6, 360 MHz) δ (ppm) 165.1 (NHCO), 163.3, 160.0 (C-thiadiazole), 156.3, 128.7, 128.4, 125.7 (Ar), 81.7, 77.6, 76.9, 74.5, 70.0 (C-1 to C-5), 61.2 (C-6), 35.0 (Cq-*t*Bu), 31.0 (CH_3). Anal. Calcd for $C_{19}H_{25}N_3O_6S$ (423.48): C, 53.89, H, 5.95; N, 9.92; S, 7.57. Found: C, 53.97; H, 6.02; N, 9.99; S, 7.50.

Acknowledgements

This work was supported by the Hungarian Scientific Research Fund (OTKA CK77712, CNK80709), TÁMOP 4.2.1./B-09/1/KONV-2010-0007 and TÁMOP-4.2.2./B-10/1-2010-0024 projects implemented through the New Hungary Development Plan, co-financed by the European Social Fund, and Bolyai Janos Research Fellowships (to MT and TD).

References

1. Kurukulasuriya, R.; Link, J. T.; Madar, D. J.; Pei, Z.; Rohde, J. J.; Richards, S. J.; Souers, A. J.; Szczepankiewicz, B. G. *Curr. Med. Chem.* **2003**, *10*, 99–121.
2. Barf, T. *Mini-Rev. Med. Chem.* **2004**, *4*, 897–908.
3. Ross, S. A.; Gulve, E. A.; Wang, M. H. *Chem. Rev.* **2004**, *104*, 1255–1282.
4. Somsák, L.; Czifrák, K.; Tóth, M.; Bokor, É.; Chrysina, E. D.; Alexacou, K. M.; Hayes, J. M.; Tiraidis, C.; Lazoura, E.; Leonidas, D. D.; Zographos, S. E.; Oikonomakos, N. G. *Curr. Med. Chem.* **2008**, *15*, 2933–2983.
5. Praly, J. P.; Vidal, S. *Mini-Rev. Med. Chem.* **2010**, *10*, 1102–1126.
6. Loughlin, W. A. *Mini-Rev. Med. Chem.* **2010**, *10*, 1139–1155.
7. Somsák, L. *C. R. Chim.* **2011**, *14*, 211–223.
8. Györgydeák, Z.; Hadady, Z.; Felföldi, N.; Krakomperger, A.; Nagy, V.; Tóth, M.; Brunyánszky, A.; Docsa, T.; Gergely, P.; Somsák, L. *Bioorg. Med. Chem.* **2004**, *12*, 4861–4870.
9. Chrysina, E. D. *Mini-Rev. Med. Chem.* **2010**, *10*, 1093–1101.
10. Chrysina, E. D.; Bokor, É.; Alexacou, K.-M.; Charavgi, M.-D.; Oikonomakos, G. N.; Zographos, S. E.; Leonidas, D. D.; Oikonomakos, N. G.; Somsák, L. *Tetrahedron: Asymmetry* **2009**, *20*, 733–740.
11. Somsák, L.; Felföldi, N.; Kónya, B.; Hüse, C.; Telepó, K.; Bokor, É.; Czifrák, K. *Carbohydr. Res.* **2008**, *343*, 2083–2093.
12. Nagy, V.; Felföldi, N.; Kónya, B.; Praly, J.-P.; Docsa, T.; Gergely, P.; Chrysina, E. D.; Tiraidis, C.; Kosmopoulou, M. N.; Alexacou, K.-M.; Konstantakaki, M.; Leonidas, D. D.; Zographos, S. E.; Oikonomakos, N. G.; Kozmon, S.; Tvaroška, I.; Somsák, L. *Bioorg. Med. Chem.* **2012**, *20*, 1801–1816.
13. Bokor, É.; Docsa, T.; Gergely, P.; Somsák, L. *Bioorg. Med. Chem.* **2010**, *18*, 1171–1180.
14. Benltifa, M.; Vidal, S.; Fenet, B.; Msaddek, M.; Goekjian, P. G.; Praly, J.-P.; Brunyánszki, A.; Docsa, T.; Gergely, P. *Eur. J. Org. Chem.* **2006**, 4242–4256.
15. Tóth, M.; Kun, S.; Bokor, É.; Benltifa, M.; Tallec, G.; Vidal, S.; Docsa, T.; Gergely, P.; Somsák, L.; Praly, J.-P. *Bioorg. Med. Chem.* **2009**, *17*, 4773–4785.
16. Chrysina, E. D.; Chajistamatiou, A.; Chegkazi, M. *Curr. Med. Chem.* **2011**, *18*, 2620–2629.
17. Somsák, L.; Nagy, V. *Tetrahedron: Asymmetry* **2000**, *11*, 1719–1727. Corrigendum 2247.
18. Tóth, M.; Somsák, L. *Carbohydr. Res.* **2003**, *338*, 1319–1325.
19. Kubota, S.; Ueda, Y.; Fujikane, K.; Toyooka, K.; Shibuya, M. *J. Org. Chem.* **1980**, *45*, 1473–1477.
20. Ősz, E.; Somsák, L.; Szilágyi, L.; Kovács, L.; Docsa, T.; Tóth, B.; Gergely, P. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 1385–1390.
21. Oikonomakos, N. G.; Kosmopolou, M.; Zographos, S. E.; Leonidas, D. D.; Somsák, L.; Nagy, V.; Praly, J.-P.; Docsa, T.; Tóth, B.; Gergely, P. *Eur. J. Biochem.* **2002**, *269*, 1684–1696.
22. Cer, R. Z.; Mudunuri, U.; Stephens, R.; Lebeda, F. J. *Nucl. Acids Res.* **2009**, *37*, W441–W445.